INOVIO Submits Conditional Marketing Authorization Application To EMA For VOCERYQ In Adults with Recurrent Respiratory Papillomatosis
Benzinga Newsdesk 9 hours ago
FDANews
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high
- VOCERYQ™, the first FDA-approved plasmid DNA-based immunotherapy, received FDA accelerated approval on October 30, 2026
- Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating HPV-related disease with high unmet need in Europe
